Damle D K, Mahajan P M, Pradhan S N, Belgaumkar V A, Gosavi A P, Tolat S N, Gokhale N R, Mhaske C B
Department of Dermatology, B.J. Medical College, Pune, Maharashtra State, India.
J Drugs Dermatol. 2008 Sep;7(9):853-6.
Mycetoma has a worldwide geographical distribution which is extremely uneven; however, it is a common disease in India and responsible for causing significant morbidity. Treatment of this condition is often a challenge for the treating dermatologist. The authors report a promising therapy for patients of actinomycotic mycetoma.
This assessment series included 18 patients with a confirmed diagnosis of actinomycetoma, and who had shown a poor response to previous treatments. Patient received a combination therapy of the Welsh regimen (amikacin along with cotrimoxazole) to which rifampicin was added as a third drug. Clinical evaluation included radiology and laboratory investigations.
Sixteen patients out of 18 completed the combination therapy, which lead to remission. Two patients were lost to follow-up. Of the 16 patients in remission, no recurrence was observed during a follow-up period of up to 18 months.
足菌肿在全球的地理分布极不均衡;然而,它在印度是一种常见疾病,会导致严重的发病率。对于治疗皮肤科医生而言,这种疾病的治疗往往是一项挑战。作者报告了一种针对放线菌性足菌肿患者的有前景的治疗方法。
该评估系列纳入了18例确诊为放线菌性足菌肿且对先前治疗反应不佳的患者。患者接受了威尔士方案(阿米卡星联合复方新诺明)的联合治疗,并添加利福平作为第三种药物。临床评估包括影像学和实验室检查。
18例患者中有16例完成了联合治疗,病情缓解。2例患者失访。在16例病情缓解的患者中,随访长达18个月期间未观察到复发。